Fig. 6: Kaplan–Meier curves for progression-free survival and overall survival with ICIs monotherapy or ICIs combined therapy.
From: Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
A, B Overall survival (A) and progression-free survival (B) with ICIs or ICIs combined therapy according to the BRAF mutation status. C, D Overall survival (C) and progression-free survival (D) for first line therapy according to the BRAF mutation status. E, F Overall survival (E) and progression-free survival (F) for second or later line therapy according to the BRAF mutation status. G, H Overall survival (G) and progression-free survival (H) with ICIs or ICIs combined therapy according to the BRAF mutation type.
